PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

famotidine Side Effects

The reactions most often reported to the FDA for famotidine (also sold as Pepcid), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

110,018
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 1995 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of famotidine come from 110,018 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 110,018 reports to the FDA Adverse Event Reporting System (FAERS) for famotidine (Pepcid): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

110,018

Reports Mentioning Death

10,287

9.4% of reports — not proof the medicine caused the death

Hospitalizations

35,591

32.4% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

NAUSEA
7,258
FATIGUE
6,866
CHRONIC KIDNEY DISEASE
6,644
DIARRHOEA
6,452
DYSPNOEA
5,202
HEADACHE
4,907
ACUTE KIDNEY INJURY
4,660
PAIN
4,619
VOMITING
4,464
DIZZINESS
4,226
RENAL FAILURE
4,104
DEATH
3,690
PNEUMONIA
3,504
ASTHENIA
3,363
PYREXIA
3,343
RASH
3,183
ARTHRALGIA
3,138
PRURITUS
2,974

Who Reports Side Effects

Gender Distribution

Female 61,566 (62%)
Male 37,547 (38%)
Unknown 106

Age Distribution

0-17 4,064 (6%)
18-44 10,919 (16%)
45-64 23,580 (34%)
65-74 16,749 (24%)
75+ 13,846 (20%)

Reporting Trend by Year

1995 2025

Reactions in Death Reports

Top reactions reported in 10,287 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 3,672
PNEUMONIA 726
RENAL FAILURE 724
CHRONIC KIDNEY DISEASE 715
ACUTE KIDNEY INJURY 712
SEPSIS 585
RESPIRATORY FAILURE 535
DYSPNOEA 486
NAUSEA 464
END STAGE RENAL DISEASE 462
DIARRHOEA 452
PYREXIA 449
CARDIAC ARREST 420
ANAEMIA 408
FATIGUE 403
HYPOTENSION 386
ASTHENIA 364
DISEASE PROGRESSION 358
VOMITING 342

Reactions in Hospitalization Reports

Top reactions in 35,591 reports where hospitalization was an outcome.

Reaction Reports
PNEUMONIA 2,739
NAUSEA 2,675
DIARRHOEA 2,463
DYSPNOEA 2,438
VOMITING 2,230
PYREXIA 2,147
FATIGUE 2,073
PAIN 1,720
FALL 1,713
ACUTE KIDNEY INJURY 1,690
ASTHENIA 1,604
HEADACHE 1,428
RENAL FAILURE 1,400
ANAEMIA 1,356
URINARY TRACT INFECTION 1,323
DIZZINESS 1,321
DEHYDRATION 1,298
ABDOMINAL PAIN 1,286
DECREASED APPETITE 1,170

Compare famotidine vs alosetron →

What the FAERS Data Reveals About famotidine Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 110,018 voluntary reports linked to famotidine and its brand equivalents (Pepcid), spanning 1995 through 2025. Of those, 10,287 (9.4%) listed death as an outcome and 35,591 (32.4%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 62% were female and 38% male; age distribution skews toward 45-64, with 23,580 reports in that bracket. The single most reported reaction is nausea with 7,258 submissions, followed by fatigue and chronic kidney disease.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.